Importance of antiresorptive therapies for patients with bone metastases from solid tumors

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 287-297

  Talreja, Draupadi B ^a  

^a Northridge Hospital Medical Center   (United States)

Author keywords

Antiresorptive therapy; Bisphosphonates; Bone metastases; Cancer; Denosumab; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER RISK; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; HABIT; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; MEDICAL CARE; MULTIPLE MYELOMA; NEOPLASM; OSTEOLYSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIMARY MEDICAL CARE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR;

EID: 84866641741     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S33983     Document Type: Review

References (92)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27(3):165-176.
2. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumor effects. Cancer Treat Rev. 2008;34(2):183-192.
3. Weinfurt KP, Li Y, Castel LD, et al. The significance of skelet al-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579-584.
4. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-822.
5. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
6. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skelet al complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
7. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skelet al metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613-2621.
8. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skelet al complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-882.
9. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
10. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skelet al complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082-1090.
11. Zometa® [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
12. Xgeva® [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2010.
13. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-593.
14. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19): 1458-1468.
15. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skelet al complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
16. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skelet al complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405.
17. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skelet al complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br J Cancer. 2004;90(6):1133-1137.
18. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246(1):67-74.
19. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1): 59-65.
20. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer. 2001;88(7):701-707. French.
21. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skelet al metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.
22. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skelet al metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-3157.
23. Morgan GJ, Davies F, Gregory W, et al. Zoledronic acid prolongs time to first skelet al-related event, progression-free survival, and overall survival versus clodronate in newly diagnosed multiple myeloma: MRC Myeloma IX trial results. Abstract 0562 presented at the 15th Congress of the European Hematology Association, June 10-13, 2010, Barcelona, Spain.
24. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010; 376(9757):1989-1999.
25. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;3:CD003474.
26. Aredia® [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
27. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(Suppl 12): 2961-2978.
28. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235-242.
29. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9(5):745-751.
30. Hadji P. Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Crit Rev Oncol Hematol. 2011;80(2):301-313.
31. Green JR, Guenther A. The backbone of progress-preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol. 2011;77 Suppl 1:S3-S12.
32. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010;37 Suppl 1:S53-S65.
33. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34(5): 453-475.
34. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010;102(7):1099-1105.
35. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.
36. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339(6):357-363.
37. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008;19(12):2007-2011.
38. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skelet al metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19(1):10-17.
39. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43(7):650-656.
40. Paterson AHG, Anderson SJ, Lembersky BC, et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy-final analysis. Abstract S2-3 presented at the CTRC-AACR San Antonio Breast Cancer Symposium, December 6-10, 2011, San Antonio, TX.
41. Mobus V, Diel IJ, Harbeck N, et al. GAIN (German Adjuvant Intergroup Node Positive) study: a phase-III multicenter trial to compare dose dense, dose intense ETC (iddETC) vs EC-TX and ibandronate vs observation in patients with node-positive primary breast cancer-1st interim EFFICACY analysis. Abstract S2-4 presented at the CTRC-AACR San Antonio Breast Cancer Symposium, December 6-10, 2011, San Antonio, TX.
42. Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol. 2008;26(Suppl 15):20s. Abstract 559.
43. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Poster 2048 presented at the 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX.
44. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11(5):421-428.
45. Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010;30(5):1807-1813.
46. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol. 2010; 21:2188-2194.
47. de Boer R, Bundred N, Eidtmann H, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Poster P5-11-01 presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX.
48. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-691.
49. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with hormone-receptor-positive early breast cancer. Abstract S1-2 presented at the CTRC-AACR San Antonio Breast Cancer Symposium, December 6-10, 2011, San Antonio, TX.
50. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-1405.
51. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol. 2005;22(2):195-201.
52. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15(4):382-389.
53. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009;125(7):1705-1709.
54. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24(2):227-230.
55. Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011;29(8):533-541.
56. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
57. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.
58. Bachmann MF, Kopf M. The role of B cells in acute and chronic infections. Curr Opin Immunol. 1999;11(3):332-339.
59. Kim HH, Shin HS, Kwak HJ, et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. FASEB J. 2003;17(14):2163-2165.
60. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20: 795-823.
61. Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skelet al and extraskelet al tissues. Bone. 1999;25(5):525-534.
62. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-980.
63. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43(2):222-229.
64. Stopeck A, Lipton A, Martin M, et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3study. Abstract P3-16-07 presented at the San Antonio Breast Cancer Symposium, December 6-10, 2011, San Antonio, TX.
65. Lipton A, Siena S, Rader M, et al. Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Poster 1249P presented at the 35th ESMO Congress, October 8-12, 2010, Milan, Italy.
66. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39-46.
67. US National Institutes of Health. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00556374?term=NCT00556374&rank=1. Accessed May 8, 2012.
68. US National Institutes of Health. ClinicalTrials. gov. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01077154?term=NCT01077154&rank=1. Accessed May 8, 2012.
69. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420-432.
70. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897-907.
71. Maxwell C, Swift R, Goode M, Doane L, Rogers M. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurs. 2003;7(4): 403-408.
72. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341-1347.
73. Coleman R, Bundred N, de Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Abstract 4082 presented at the 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX.
74. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875-4882.
75. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137-145.
76. Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26(36):5904-5909.
77. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. Aust Endod J. 2009;35:119-130.
78. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol. 2010; 30(6):548-556.
79. Launay-Vacher V, Izzedine H, Rey JB, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004;10(5):CR209-CR212.
80. Launay-Vacher V, Spano JP, Janus N, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70(2):124-133.
81. Stevens LA, Li S, Wang C, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010;55(3 Suppl 2):S23-S33.
82. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer. 2007;110(6):1376-1384.
83. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39 Suppl 1:S1-S266.
84. Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control. 2000;7(6):548-556.
85. Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol. 2009;5(8):450-462.
86. Launay-Vacher V, Janus N, Karie S, Deray G. Letter. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007;17(6):1340-1341.
87. Bondronat [summary of product characteristics]. Roche Diagnostics GmbH and Roche Products Limited. Available from: http://www.medicines.org.uk/EMC/printfriendlydocument.aspx?documentid=8600&compPublished. Revised August 9, 2011. Accessed May 8, 2012.
88. Bondronat [Professional Information Swiss Drug Compendium]. Roche Pharma (Schweiz) AG. Available from: http://www.kompendium.ch/MonographieTxt.aspx?lang=fr&MonType=fi. Published April, 2009. Accessed May 8, 2012.
89. Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skelet al-related events in cancer patients. Support Care Cancer. 2012;20(7):1353-1360.
90. Snedecor SJ, Carter JA, Kaura S, Botteman MF. Cost-effectiveness of zoledronic acid versus denosumab in prevention of skelet al-related events in castration-resistant prostate cancer metastatic to the bone. Abstract 4581 presented at the 2011ASCO Annual Meeting, June 3-7, 2011, Chicago, IL.
91. Snedecor SJ, Carter JA, Kaura S, Botteman MF. Cost-effectiveness of denosumab versus zoledronic acid in the management of skelet al metastases secondary to breast cancer. Clin Ther. 2012;34(6):1334-1349.
92. Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skelet al-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2012;15(4):712-723.